source
- Kodiak Sciences' Zenkuda shows non-inferior six-month dosing vs Eylea, shares doubleFour years ago Kodiak Sciences saw its share price plunge about 80% after its lead eye-disease candidate failed a head-to-head trial against Regeneron's Eylea, wiping out roughly $2 billion in mark…
- Novartis pays $575 million upfront for worldwide rights to Abogen’s CD19xCD3 mRNA T-cell engagerNovartis announced it will pay Abogen Biosciences $575 million upfront for exclusive worldwide rights to its lead early‑stage CD19xCD3 mRNA T‑cell engager. The agreement gives Novartis access to t…